Worth reading
57In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
311
¥ million (year-on-year increase in operating income)Wording
Conditional
How definitive the wording is.Contents of this document
Earnings presentationFull fiscal year ended May 202613 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥7,841 million+17.9%
Operating profit¥743 million+71.9%
Ordinary income¥707 million+64.5%
Net income¥163 million-32.4%
Selling, general and administrative expenses¥1,615 million
Gross Profit Margin
Rate30.1%
Operating profit margin
Rate9.5%
Results for the three months of the current quarterThe presentation charts quarterly trends in revenue and operating margin, but specific figures for the three-month period are Not disclosed
Full-year earnings forecast
Net Sales
¥7,100 million
Operating profit
¥550 million
Ordinary income
¥500 million
Net income for the current fiscal year
¥350 million
Dividend
¥26 per share
Depreciation and amortization
¥139 million
Capital expenditures
¥455 million
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Above the initial forecast / substantially above the original planBreakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Operating profit
Revenue Growth350
Improvement in cost ratio47
Increase in SG&A expenses-87
Operating profit by business
Increase in gross profit from the pharmaceutical business197
Increase in gross profit from the health food business98
Increase in gross profit from the chemical products business103
Increase in SG&A expenses-87
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
The outlook assumes withdrawal from the health food business and the opening of a chemical development center, but numerical assumptions for foreign exchange rates, raw material prices and volumes are Not disclosedNew initiatives
- Completed withdrawal from the health food business
- Installation of a small-scale continuous crystallizer and establishment of flow synthesis technology
- Patent application and joint research concerning PFAS treatment
- Opening of a chemical development center in a renovated former jelly factory (scheduled to begin operations in July 2027; investment of ¥350 million)
- Expansion of the medium-term management plan into a five-year plan through the fiscal year ending May 2031
Key KPIsA metric the company considers important as a management benchmark.
- Free cash flow¥570 million
- Equity ratio40.6 %Year on year against the same period last yearDown 6.0 percentage points from the end of the previous fiscal year
- Number of employees205 People
Segment results
Pharmaceuticals Business
Net Sales
¥3,986 million+23.9%
Operating profit
¥634 million+33.8%
Health Foods Business
Net Sales
¥1,186 million+13.7%
Operating profit
¥18 million
Chemicals Business
Net Sales
¥2,669 million+11.6%
Operating profit
¥91 million+59.7%
Medium-term management plan targets
Net Sales
Target value¥10,800 million
Target fiscal yearFiscal year ending May 2031
Operating profit margin
Target value10 %
Target fiscal yearFiscal year ending May 2031
EBITDA
Target value¥1,400 million
Target fiscal yearFiscal year ending May 2031
Market Size / Share
The presentation refers to market trends, but numerical figures for market size and share are Not disclosedNumber of stores and locations
Locations are disclosed, but the number of openings and closures during the period is Not disclosedNumber of employees
Number of Employees205 People
Record dateEnd of May 2026
Capital expenditures
¥246 million actual for the fiscal year ended May 2026
Annual Dividend
Annual dividend per share¥26 per share
Payout ratio
The continuation of the progressive dividend policy is stated, but numerical figures for the payout ratio and other metrics are Not disclosed| Item | Details |
|---|---|
| Document type | Earnings presentation |
| Fiscal Period Covered | Full fiscal year ended May 2026 |
| Net Sales | ¥7,841 million (YoY +17.9%) |
| Operating profit | ¥743 million (YoY +71.9%) |
| Ordinary income | ¥707 million (YoY +64.5%) |
| Net income | ¥163 million (YoY -32.4%) |
| Gross Profit Margin | Rate 30.1% / Year-on-year change (points) Not disclosed |
| Operating profit margin | Rate 9.5% / Year-on-year change (points) Not disclosed |
| Selling, general and administrative expenses | ¥1,615 million |
| Results for the three months of the current quarter | The presentation charts quarterly trends in revenue and operating margin, but specific figures for the three-month period are Not disclosed |
| Full-year earnings forecast | Net Sales ¥7,100 million / Operating profit ¥550 million / Ordinary income ¥500 million / Net income for the current fiscal year ¥350 million / Dividend ¥26 per share / Depreciation and amortization ¥139 million / Capital expenditures ¥455 million |
| Self-assessment against the plan | Above the initial forecast / substantially above the original plan |
| Segment results | Pharmaceuticals Business Net Sales ¥3,986 million (YoY +23.9%) / Operating profit ¥634 million (YoY +33.8%) / Health Foods Business Net Sales ¥1,186 million (YoY +13.7%) / Operating profit ¥18 million / Chemicals Business Net Sales ¥2,669 million (YoY +11.6%) / Operating profit ¥91 million (YoY +59.7%) |
| Breakdown of Factors Affecting the Change | Operating profit Revenue Growth 350 / Improvement in cost ratio 47 / Increase in SG&A expenses -87 / Operating profit by business Increase in gross profit from the pharmaceutical business 197 / Increase in gross profit from the health food business 98 / Increase in gross profit from the chemical products business 103 / Increase in SG&A expenses -87 |
| Key KPIs | Indicator name Free cash flow / Value ¥570 million / Year on year against the same period last year Not disclosed, Indicator name Equity ratio / Value 40.6 % / Year on year against the same period last year Down 6.0 percentage points from the end of the previous fiscal year, Indicator name Number of employees / Value 205 People / Year on year against the same period last year Not disclosed |
| Number of stores and locations | Locations are disclosed, but the number of openings and closures during the period is Not disclosed |
| Number of employees | Number of Employees 205 People / Record date End of May 2026 / Changes during the period and hiring plan Not disclosed |
| Assumptions Underlying the Business Outlook | The outlook assumes withdrawal from the health food business and the opening of a chemical development center, but numerical assumptions for foreign exchange rates, raw material prices and volumes are Not disclosed |
| Medium-term management plan targets | Net Sales Target value ¥10,800 million / Target fiscal year Fiscal year ending May 2031 / Operating profit margin Target value 10 % / Target fiscal year Fiscal year ending May 2031 / EBITDA Target value ¥1,400 million / Target fiscal year Fiscal year ending May 2031 |
| Annual Dividend | Annual dividend per share ¥26 per share / Interim and Year-End Breakdown Not disclosed |
| Payout ratio | The continuation of the progressive dividend policy is stated, but numerical figures for the payout ratio and other metrics are Not disclosed |
| Capital expenditures | ¥246 million (actual for the fiscal year ended May 2026) |
| Market Size / Share | The presentation refers to market trends, but numerical figures for market size and share are Not disclosed |
| New initiatives | Completed withdrawal from the health food business, Installation of a small-scale continuous crystallizer and establishment of flow synthesis technology, Patent application and joint research concerning PFAS treatment, Opening of a chemical development center in a renovated former jelly factory (scheduled to begin operations in July 2027; investment of ¥350 million), Expansion of the medium-term management plan into a five-year plan through the fiscal year ending May 2031 |
Items this document does not state (7)
Progress against full-year forecastUnit price and quantity metricsRisk amount incorporated into the outlookFinancial targetsAcquisition of treasury sharesOrders received and order backlogKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Sales increased across all businesses, and gross profit rose as the cost ratio improved slightly. Selling, general and administrative expenses increased, mainly due to higher personnel expenses. Net income declined because the Company recorded an extraordinary loss associated with a review of the pharmaceutical business plan.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.